array(40) {
  [0]=>
  string(4) "8228"
  ["article_id"]=>
  string(4) "8228"
  [1]=>
  string(85) "Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock"
  ["article_title"]=>
  string(85) "Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock"
  [2]=>
  string(150) "NEW YORK, March  11, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the dev"
  ["short_description"]=>
  string(150) "NEW YORK, March  11, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the dev"
  [3]=>
  string(653) "
NEW YORK, March  11, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 1,125,000 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.
"
  ["description"]=>
  string(653) "
NEW YORK, March  11, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 1,125,000 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(155) "http://www.globenewswire.com/news-release/2020/03/12/1999130/0/en/Seelos-Therapeutics-Announces-Pricing-of-4-5-Million-Public-Offering-of-Common-Stock.html"
  ["blog_url"]=>
  string(155) "http://www.globenewswire.com/news-release/2020/03/12/1999130/0/en/Seelos-Therapeutics-Announces-Pricing-of-4-5-Million-Public-Offering-of-Common-Stock.html"
  [15]=>
  string(19) "2020-03-12 08:30:00"
  ["add_date"]=>
  string(19) "2020-03-12 08:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:55:49"
  ["create_at"]=>
  string(19) "2020-03-12 15:55:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8229"
  ["article_id"]=>
  string(4) "8229"
  [1]=>
  string(80) "123Dentist Announces Major Addition of We Care Dental Group to 123Dentist Family"
  ["article_title"]=>
  string(80) "123Dentist Announces Major Addition of We Care Dental Group to 123Dentist Family"
  [2]=>
  string(150) "TORONTO and VANCOUVER, British Columbia, March  11, 2020  (GLOBE NEWSWIRE) -- 123Dentist formally welcomes We Care Dental, its 13 practices and over 2"
  ["short_description"]=>
  string(150) "TORONTO and VANCOUVER, British Columbia, March  11, 2020  (GLOBE NEWSWIRE) -- 123Dentist formally welcomes We Care Dental, its 13 practices and over 2"
  [3]=>
  string(393) "
TORONTO and VANCOUVER, British Columbia, March  11, 2020  (GLOBE NEWSWIRE) -- 123Dentist formally welcomes We Care Dental, its 13 practices and over 200 team members across the Greater Toronto area.  With this recent addition, the 123Dentist family expands its reach to over 175 supported practices and 2,500 employees in Ontario, British Columbia, Alberta, Manitoba, and Quebec.
"
  ["description"]=>
  string(393) "
TORONTO and VANCOUVER, British Columbia, March  11, 2020  (GLOBE NEWSWIRE) -- 123Dentist formally welcomes We Care Dental, its 13 practices and over 200 team members across the Greater Toronto area.  With this recent addition, the 123Dentist family expands its reach to over 175 supported practices and 2,500 employees in Ontario, British Columbia, Alberta, Manitoba, and Quebec.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(151) "http://www.globenewswire.com/news-release/2020/03/11/1999100/0/en/123Dentist-Announces-Major-Addition-of-We-Care-Dental-Group-to-123Dentist-Family.html"
  ["blog_url"]=>
  string(151) "http://www.globenewswire.com/news-release/2020/03/11/1999100/0/en/123Dentist-Announces-Major-Addition-of-We-Care-Dental-Group-to-123Dentist-Family.html"
  [15]=>
  string(19) "2020-03-12 05:57:00"
  ["add_date"]=>
  string(19) "2020-03-12 05:57:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:55:49"
  ["create_at"]=>
  string(19) "2020-03-12 15:55:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8230"
  ["article_id"]=>
  string(4) "8230"
  [1]=>
  string(55) "Zealand Pharma convenes its Annual General Meeting 2020"
  ["article_title"]=>
  string(55) "Zealand Pharma convenes its Annual General Meeting 2020"
  [2]=>
  string(43) "Company Announcement – No. 04 / 2020"
  ["short_description"]=>
  string(43) "Company Announcement – No. 04 / 2020"
  [3]=>
  string(84) "
Company Announcement – No. 04 / 2020
"
  ["description"]=>
  string(84) "
Company Announcement – No. 04 / 2020
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(126) "http://www.globenewswire.com/news-release/2020/03/11/1999099/0/en/Zealand-Pharma-convenes-its-Annual-General-Meeting-2020.html"
  ["blog_url"]=>
  string(126) "http://www.globenewswire.com/news-release/2020/03/11/1999099/0/en/Zealand-Pharma-convenes-its-Annual-General-Meeting-2020.html"
  [15]=>
  string(19) "2020-03-12 05:55:00"
  ["add_date"]=>
  string(19) "2020-03-12 05:55:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:55:49"
  ["create_at"]=>
  string(19) "2020-03-12 15:55:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8231"
  ["article_id"]=>
  string(4) "8231"
  [1]=>
  string(95) "Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019"
  ["article_title"]=>
  string(95) "Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019"
  [2]=>
  string(43) "Company announcement – No. 03 / 2020"
  ["short_description"]=>
  string(43) "Company announcement – No. 03 / 2020"
  [3]=>
  string(67) "
Company announcement – No. 03 / 2020
"
  ["description"]=>
  string(67) "
Company announcement – No. 03 / 2020
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(165) "http://www.globenewswire.com/news-release/2020/03/11/1999095/0/en/Zealand-Pharma-advances-pipeline-and-maintains-strong-cash-position-full-year-results-for-2019.html"
  ["blog_url"]=>
  string(165) "http://www.globenewswire.com/news-release/2020/03/11/1999095/0/en/Zealand-Pharma-advances-pipeline-and-maintains-strong-cash-position-full-year-results-for-2019.html"
  [15]=>
  string(19) "2020-03-12 05:50:00"
  ["add_date"]=>
  string(19) "2020-03-12 05:50:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:55:49"
  ["create_at"]=>
  string(19) "2020-03-12 15:55:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8232"
  ["article_id"]=>
  string(4) "8232"
  [1]=>
  string(62) "Globus Medical Announces $200 Million Share Repurchase Program"
  ["article_title"]=>
  string(62) "Globus Medical Announces $200 Million Share Repurchase Program"
  [2]=>
  string(150) "AUDUBON, Pa., March  11, 2020  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the "
  ["short_description"]=>
  string(150) "AUDUBON, Pa., March  11, 2020  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the "
  [3]=>
  string(283) "
AUDUBON, Pa., March  11, 2020  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the Board of Directors authorized the repurchase of $200 million of the Company’s common stock.
"
  ["description"]=>
  string(283) "
AUDUBON, Pa., March  11, 2020  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the Board of Directors authorized the repurchase of $200 million of the Company’s common stock.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(132) "http://www.globenewswire.com/news-release/2020/03/11/1999089/0/en/Globus-Medical-Announces-200-Million-Share-Repurchase-Program.html"
  ["blog_url"]=>
  string(132) "http://www.globenewswire.com/news-release/2020/03/11/1999089/0/en/Globus-Medical-Announces-200-Million-Share-Repurchase-Program.html"
  [15]=>
  string(19) "2020-03-12 05:40:00"
  ["add_date"]=>
  string(19) "2020-03-12 05:40:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:55:50"
  ["create_at"]=>
  string(19) "2020-03-12 15:55:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8225"
  ["article_id"]=>
  string(4) "8225"
  [1]=>
  string(46) "Insulin Makers Support CMS Plan for $35 Copays"
  ["article_title"]=>
  string(46) "Insulin Makers Support CMS Plan for $35 Copays"
  [2]=>
  string(153) "&#nl        The Centers for Medicare and Medicaid Services (CMS) unveiled a model program that will cap Medicare Part D out-of-pocket insulin costs for s"
  ["short_description"]=>
  string(153) "&#nl        The Centers for Medicare and Medicaid Services (CMS) unveiled a model program that will cap Medicare Part D out-of-pocket insulin costs for s"
  [3]=>
  string(312) "&#nl        The Centers for Medicare and Medicaid Services (CMS) unveiled a model program that will cap Medicare Part D out-of-pocket insulin costs for seniors at $35 per month, and all three manufacturers for the U.S. market — Eli Lilly, Sanofi and Novo Nordisk — said they will take part.&#nl      "
  ["description"]=>
  string(312) "&#nl        The Centers for Medicare and Medicaid Services (CMS) unveiled a model program that will cap Medicare Part D out-of-pocket insulin costs for seniors at $35 per month, and all three manufacturers for the U.S. market — Eli Lilly, Sanofi and Novo Nordisk — said they will take part.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(85) "https://www.fdanews.com/articles/196212-insulin-makers-support-cms-plan-for-35-copays"
  ["blog_url"]=>
  string(85) "https://www.fdanews.com/articles/196212-insulin-makers-support-cms-plan-for-35-copays"
  [15]=>
  string(19) "2020-03-12 05:27:45"
  ["add_date"]=>
  string(19) "2020-03-12 05:27:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:50:42"
  ["create_at"]=>
  string(19) "2020-03-12 15:50:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8571"
  ["article_id"]=>
  string(4) "8571"
  [1]=>
  string(113) "New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020"
  ["article_title"]=>
  string(113) "New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020"
  [2]=>
  string(150) "BOSTON--(BUSINESS WIRE)-- March 11, 2020 -- Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from clinical and preclinical studies exploring "
  ["short_description"]=>
  string(150) "BOSTON--(BUSINESS WIRE)-- March 11, 2020 -- Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from clinical and preclinical studies exploring "
  [3]=>
  string(250) "BOSTON--(BUSINESS WIRE)-- March 11, 2020 -- Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from clinical and preclinical studies exploring the use of GS-6207, an investigational, novel, first-in-class inhibitor of HIV-1 capsid function,..."
  ["description"]=>
  string(250) "BOSTON--(BUSINESS WIRE)-- March 11, 2020 -- Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from clinical and preclinical studies exploring the use of GS-6207, an investigational, novel, first-in-class inhibitor of HIV-1 capsid function,..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/new-clinical-study-data-gilead-s-investigational-hiv-1-capsid-inhibitor-gs-6207-presented-croi-2020-18466.html?utm_source=ddc&utm_medium=rss&utm_campaign=New+Clinical+Study+Data+for+Gilead%E2%80%99s+Investigational+HIV-1+Capsid+Inhibitor+GS-6207+Presented+at+CRO"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/new-clinical-study-data-gilead-s-investigational-hiv-1-capsid-inhibitor-gs-6207-presented-croi-2020-18466.html?utm_source=ddc&utm_medium=rss&utm_campaign=New+Clinical+Study+Data+for+Gilead%E2%80%99s+Investigational+HIV-1+Capsid+Inhibitor+GS-6207+Presented+at+CRO"
  [15]=>
  string(19) "2020-03-12 05:03:32"
  ["add_date"]=>
  string(19) "2020-03-12 05:03:32"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8233"
  ["article_id"]=>
  string(4) "8233"
  [1]=>
  string(83) "Conatus Pharmaceuticals Reports 2019 Financial Results and Strategic Process Update"
  ["article_title"]=>
  string(83) "Conatus Pharmaceuticals Reports 2019 Financial Results and Strategic Process Update"
  [2]=>
  string(150) "SAN DIEGO, March  11, 2020  (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter an"
  ["short_description"]=>
  string(150) "SAN DIEGO, March  11, 2020  (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter an"
  [3]=>
  string(267) "
SAN DIEGO, March  11, 2020  (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its strategic process.
"
  ["description"]=>
  string(267) "
SAN DIEGO, March  11, 2020  (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its strategic process.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(154) "http://www.globenewswire.com/news-release/2020/03/11/1999068/0/en/Conatus-Pharmaceuticals-Reports-2019-Financial-Results-and-Strategic-Process-Update.html"
  ["blog_url"]=>
  string(154) "http://www.globenewswire.com/news-release/2020/03/11/1999068/0/en/Conatus-Pharmaceuticals-Reports-2019-Financial-Results-and-Strategic-Process-Update.html"
  [15]=>
  string(19) "2020-03-12 04:45:00"
  ["add_date"]=>
  string(19) "2020-03-12 04:45:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:55:50"
  ["create_at"]=>
  string(19) "2020-03-12 15:55:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8261"
  ["article_id"]=>
  string(4) "8261"
  [1]=>
  string(63) "Xcelerating Life Sciences San Diego Will Be Delivered Digitally"
  ["article_title"]=>
  string(63) "Xcelerating Life Sciences San Diego Will Be Delivered Digitally"
  [2]=>
  string(150) "At Xconomy, we are here to serve the global biotech community and help biotech and pharma companies connect, do business, and find investment opportun"
  ["short_description"]=>
  string(150) "At Xconomy, we are here to serve the global biotech community and help biotech and pharma companies connect, do business, and find investment opportun"
  [3]=>
  string(334) "At Xconomy, we are here to serve the global biotech community and help biotech and pharma companies connect, do business, and find investment opportunities. We take this role seriously, and over the last week we have been engaged with many of you on how to deliver the value that Xcelerating Life Sciences San Diego provides […]"
  ["description"]=>
  string(334) "At Xconomy, we are here to serve the global biotech community and help biotech and pharma companies connect, do business, and find investment opportunities. We take this role seriously, and over the last week we have been engaged with many of you on how to deliver the value that Xcelerating Life Sciences San Diego provides […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(104) "https://xconomy.com/national/2020/03/11/xcelerating-life-sciences-san-diego-will-be-delivered-digitally/"
  ["blog_url"]=>
  string(104) "https://xconomy.com/national/2020/03/11/xcelerating-life-sciences-san-diego-will-be-delivered-digitally/"
  [15]=>
  string(19) "2020-03-12 04:33:34"
  ["add_date"]=>
  string(19) "2020-03-12 04:33:34"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:09"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8234"
  ["article_id"]=>
  string(4) "8234"
  [1]=>
  string(66) "Atreca Reports Fourth Quarter and Full Year 2019 Financial Results"
  ["article_title"]=>
  string(66) "Atreca Reports Fourth Quarter and Full Year 2019 Financial Results"
  [2]=>
  string(150) "SOUTH SAN FRANCISCO, Calif., March  11, 2020  (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused"
  ["short_description"]=>
  string(150) "SOUTH SAN FRANCISCO, Calif., March  11, 2020  (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused"
  [3]=>
  string(465) "
SOUTH SAN FRANCISCO, Calif., March  11, 2020  (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of recent developments.
"
  ["description"]=>
  string(465) "
SOUTH SAN FRANCISCO, Calif., March  11, 2020  (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of recent developments.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(137) "http://www.globenewswire.com/news-release/2020/03/11/1999059/0/en/Atreca-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results.html"
  ["blog_url"]=>
  string(137) "http://www.globenewswire.com/news-release/2020/03/11/1999059/0/en/Atreca-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results.html"
  [15]=>
  string(19) "2020-03-12 04:30:00"
  ["add_date"]=>
  string(19) "2020-03-12 04:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:55:50"
  ["create_at"]=>
  string(19) "2020-03-12 15:55:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8235"
  ["article_id"]=>
  string(4) "8235"
  [1]=>
  string(113) "Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights"
  ["article_title"]=>
  string(113) "Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights"
  [2]=>
  string(150) "WARREN, N.J., March  11, 2020  (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and comm"
  ["short_description"]=>
  string(150) "WARREN, N.J., March  11, 2020  (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and comm"
  [3]=>
  string(455) "
WARREN, N.J., March  11, 2020  (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported audited financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on recent developments in its business.
"
  ["description"]=>
  string(455) "
WARREN, N.J., March  11, 2020  (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported audited financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on recent developments in its business.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(184) "http://www.globenewswire.com/news-release/2020/03/11/1999060/0/en/Aquestive-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results-and-Recent-Business-Highlights.html"
  ["blog_url"]=>
  string(184) "http://www.globenewswire.com/news-release/2020/03/11/1999060/0/en/Aquestive-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results-and-Recent-Business-Highlights.html"
  [15]=>
  string(19) "2020-03-12 04:30:00"
  ["add_date"]=>
  string(19) "2020-03-12 04:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:55:50"
  ["create_at"]=>
  string(19) "2020-03-12 15:55:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8263"
  ["article_id"]=>
  string(4) "8263"
  [1]=>
  string(43) "StreamOne R from PAXXUS Wins Several Awards"
  ["article_title"]=>
  string(43) "StreamOne R from PAXXUS Wins Several Awards"
  [2]=>
  string(153) "&#nlStreamOne R Retortable Recycle-Ready Polyester from PAXXUS has been recognized in the Flexible Packaging Association’s "
  ["short_description"]=>
  string(153) "&#nlStreamOne R Retortable Recycle-Ready Polyester from PAXXUS has been recognized in the Flexible Packaging Association’s "
  [3]=>
  string(3693) "&#nl
StreamOne R Retortable Recycle-Ready Polyester from PAXXUS has been recognized in the Flexible Packaging Association’s annual competition with several awards: a gold award in sustainability, a gold award in technical innovation, and a silver award in packaging excellence.
&#nl
“Receiving multiple FPA awards for StreamOne R is the ultimate validation of PAXXUS’s long-term commitment toward developing leading edge technology for the evolving circular economy,” Dwane Hahn, vice president of sales and marketing for PAXXUS, told MD+DI.
&#nl
Originally designed for a food application that required ultra-high barriers to maintain taste quality and shelf-life requirements, StreamOne R is also proposed for use in medical kits and drug-delivery systems.
&#nl
The all-polyester StreamOne R was developed for applications requiring retort or autoclave sterilization. In its submission to FPA, PAXXUS explained that singe-stream options have been limited for high-barrier packaging that must undergo high-temperature processing. “Historically, a polypropylene paired with a high-barrier oriented polypropylene (oPP) has been the only choice. Unfortunately, the barrier offered by high-barrier oPP is significantly degraded upon retort or autoclave sterilization,” according to the company.
&#nl
PAXXUS explained that StreamOne R is the first all-polyester packaging solution that provides an ultra-high barrier and hermetic seals even after exposure to retort/autoclave cycles, the company reported. After sterilization, it has a barrier of 0.01 cc/100 in.2 day atm and moisture barrier of 0.02 g/100 in.2 day.
&#nl
In addition to being presented as an alternative to oPP, StreamOne R is also suggested as an alternative for aluminum foil structures for applications requiring protection from moisture and/or oxygen. “Aluminum foil is a very energy intensive material to manufacture,” the company explained in its submission. “The production of aluminum alone consumes approximately 54 MJ/kg. The energy savings by eliminating the use of aluminum foil for the barrier layer ranges from an impressive 1.0 MJ/m2 for 0.00028 in. aluminum foil to 3.7 MJ/m2 for 0.001 in. aluminum foil.”
&#nl
Another accomplishment of StreamOne R is its broad sealing window described by PAXXUS as “well below the melting point of oriented polyester yet significantly above the 120-130°C (250-266°F) retort/autoclave processing temperatures.” The result is a seal that will withstand under extreme retort/autoclave cycles.
&#nl
Earning a gold award in sustainability, StreamOne R offers the chance to recycle an ultra-high barrier, retortable packaging material in a single-polymer (#1 polyester) recycling stream. According to the company submission, “the oxide barrier coating is only angstroms thick and therefore does not impede recyclability. Post-industrial waste can be easily recycled and packages made with StreamOne R are recycle-ready for the consumer-waste stream.”
"
  ["description"]=>
  string(3693) "&#nl
StreamOne R Retortable Recycle-Ready Polyester from PAXXUS has been recognized in the Flexible Packaging Association’s annual competition with several awards: a gold award in sustainability, a gold award in technical innovation, and a silver award in packaging excellence.
&#nl
“Receiving multiple FPA awards for StreamOne R is the ultimate validation of PAXXUS’s long-term commitment toward developing leading edge technology for the evolving circular economy,” Dwane Hahn, vice president of sales and marketing for PAXXUS, told MD+DI.
&#nl
Originally designed for a food application that required ultra-high barriers to maintain taste quality and shelf-life requirements, StreamOne R is also proposed for use in medical kits and drug-delivery systems.
&#nl
The all-polyester StreamOne R was developed for applications requiring retort or autoclave sterilization. In its submission to FPA, PAXXUS explained that singe-stream options have been limited for high-barrier packaging that must undergo high-temperature processing. “Historically, a polypropylene paired with a high-barrier oriented polypropylene (oPP) has been the only choice. Unfortunately, the barrier offered by high-barrier oPP is significantly degraded upon retort or autoclave sterilization,” according to the company.
&#nl
PAXXUS explained that StreamOne R is the first all-polyester packaging solution that provides an ultra-high barrier and hermetic seals even after exposure to retort/autoclave cycles, the company reported. After sterilization, it has a barrier of 0.01 cc/100 in.2 day atm and moisture barrier of 0.02 g/100 in.2 day.
&#nl
In addition to being presented as an alternative to oPP, StreamOne R is also suggested as an alternative for aluminum foil structures for applications requiring protection from moisture and/or oxygen. “Aluminum foil is a very energy intensive material to manufacture,” the company explained in its submission. “The production of aluminum alone consumes approximately 54 MJ/kg. The energy savings by eliminating the use of aluminum foil for the barrier layer ranges from an impressive 1.0 MJ/m2 for 0.00028 in. aluminum foil to 3.7 MJ/m2 for 0.001 in. aluminum foil.”
&#nl
Another accomplishment of StreamOne R is its broad sealing window described by PAXXUS as “well below the melting point of oriented polyester yet significantly above the 120-130°C (250-266°F) retort/autoclave processing temperatures.” The result is a seal that will withstand under extreme retort/autoclave cycles.
&#nl
Earning a gold award in sustainability, StreamOne R offers the chance to recycle an ultra-high barrier, retortable packaging material in a single-polymer (#1 polyester) recycling stream. According to the company submission, “the oxide barrier coating is only angstroms thick and therefore does not impede recyclability. Post-industrial waste can be easily recycled and packages made with StreamOne R are recycle-ready for the consumer-waste stream.”
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(65) "https://www.mddionline.com/streamone-r-paxxus-wins-several-awards"
  ["blog_url"]=>
  string(65) "https://www.mddionline.com/streamone-r-paxxus-wins-several-awards"
  [15]=>
  string(19) "2020-03-12 04:22:34"
  ["add_date"]=>
  string(19) "2020-03-12 04:22:34"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:14"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}